# Solid performance to continue

### **Our view**

CRISIL delivered a robust operating performance in Q1 CY22 (4% Revenue/16-17% EBITDA & Earnings beat) characterized by multi-year high revenue growth of 20% yoy and EBITDA margin of 29.6%. The strong growth performance was driven by a) improved growth momentum in domestic ratings business (continuous market share gains), b) sustained traction in GR&RS business underpinned by strong demand for core offerings in research, risk, regulatory support, and transformation, capabilities to tap new opportunities and new client additions, c) strong performance of India Research business on continued buoyancy in capital markets and economic recovery and d) an integrated approach in GBA business driving wallet share gains within key clients and new client additions. Management remains sanguine about growth momentum in global research/benchmarking analytics businesses and about market share in the domestic ratings business.

EBITDA margin was higher 240 bps qoq and 390 bps yoy and the absolute growth in EBITDA was 38% yoy. Margins were slightly suppressed in Q1 CY21 on account of lower profitability of Greenwich (transitional period). The margin expansion came through despite high people cost inflation on account of operating leverage of non-employee cost. In our view, healthy growth in domestic ratings, traction in high-margin services within GR&RS and significant profitability turnaround in Greenwich (was profitable for whole 2021 after starting with a loss in Q1) have been key margin drivers in recent quarters. As per management, significant room for operating leverage exists in each business and attrition is being managed within the threshold.

We raise earnings estimates by 4-5% across CY22-24 by lifting growth and margin assumptions on the back of strong performance delivery in Q1 CY22 and positive management commentary about concurrent trends in market/wallet share in various businesses and readiness/capabilities to tap evolving opportunities (related to ESG and others). We estimate 15%/23% consolidated revenue/PBT CAGR over CY21-24 and ~400 bps margin expansion through the period. Improved margin and growth will cause RoE to expand by 6 ppt to 38% in CY24. Stock trades at 41x 1-yr rolling fwd. P/E, and its peak valuation has been around 55x in the past seven years. Multiple is expected to re-rate on prospects of substantial RoE expansion. Reiterate BUY and raise 12m PT to Rs4100 (earlier Rs3750).

#### **Exhibit 1: Result table**

Q1CY22	Q4CY21	QoQ	Q1CY21	YoY
5,949	7,060	-15.7%	4,952	20.1%
3,198	3,922	-18.5%	2,694	18.7%
747	776	-3.7%	780	-4.2%
4,187	5,135	-18.5%	3,677	13.9%
1,763	1,925	-8.4%	1,275	38.3%
201	134	49.7%	135	49.5%
18	19	-0.5%	26	-29.8%
252	246	2.4%	278	-9.3%
1,693	2,253	-24.8%	1,105	53.2%
477	567	-15.8%	270	76.8%
1,216	1,686	-27.9%	835	45.6%
	5,949 3,198 747 4,187 1,763 201 18 252 1,693 477	5,949         7,060           3,198         3,922           747         776           4,187         5,135           1,763         1,925           201         134           18         19           252         246           1,693         2,253           477         567	5,949         7,060         -15.7%           3,198         3,922         -18.5%           747         776         -3.7%           4,187         5,135         -18.5%           1,763         1,925         -8.4%           201         134         49.7%           18         19         -0.5%           252         246         2.4%           1,693         2,253         -24.8%	5,9497,060-15.7%4,9523,1983,922-18.5%2,694747776-3.7%7804,1875,135-18.5%3,6771,7631,925-8.4%1,27520113449.7%1351819-0.5%262522462.4%2781,6932,253-24.8%1,105477567-15.8%270



Reco	:	BUY
СМР	:	Rs 3,337
Target Price	:	Rs 4,100
Potential Return	:	22.8%

#### Stock data (as on Apr 25, 2022)

Nifty	16,954
52 Week h/l (Rs)	3575 / 1820
Market cap (Rs/USD mn)	243507 / 3175
Outstanding Shares (mn)	73
6m Avg t/o (Rs mn):	193
Div yield (%):	1.2
Bloomberg code:	CRISIL IN
NSE code:	CRISIL

#### Stock performance



#### Shareholding pattern

Promoter	66.8%
FII+DII	13.7%
Others	19.5%

$\Delta$ in stance			
(1-Yr)	New	Old	
Rating	BUY	BUY	
Target Price	4,100	3,750	

#### $\Delta$ in earnings estimates

	CY22e	CY23e	CY24e
EPS (New)	76.1	90.9	108.5
EPS (Old)	73.2	87.3	103.9
% change	4.0%	4.1%	4.4%

Financial Summary							
(Rs mn)	CY22E	CY23E	CY24E				
Net Revenue	26,976	30,780	35,176				
EBIDTA	7,688	9,009	10,597				
Margin (%)	28.5%	29.3%	30.1%				
PAT	5,550	6,629	7,910				
Growth (%)	19.1%	19.4%	19.3%				
ROE (%)	33.4%	35.9%	38.4%				
EPS (Rs)	76.1	90.9	108.5				
P/E (x)	43.8	36.7	30.8				
BV (Rs)	239	267	299				
P/BV (x)	13.9	12.5	11.2				

RAJIV MEHTA Lead Analyst
rajiv.mehta@ysil.in
+91 22 6885 0521
MANUJ OBEROI, Associate





# **KEY CON-CALL HIGHLIGHTS**

#### **Domestic Ratings Business**

- Strong growth for CRISIL despite tepid trends in lending markets continuance of market share gains that started post the IL&FS event
- Corp Bond issuances declined by 22-23% in CY21 and Q1 CY22 on rising and volatile interest rates - issuances from NBFC sector, one of the largest issuer segments, were muted - No. of issuers dipped by 26% in CY21
- There has been a reduction in the no. of clients (nearly halved) seeking BLR rating in the past 3-4 years due to increase in minimum exposure threshold by large private banks (to near Rs500mn) – but this headwind has fully played out
- CRISIL's analytical rigor and quality of ratings (reflected in long-run avg default rates) has been much superior than other CRAs across rating categories – this is significantly valued by investors and issuers
- Stressed assets ratings business while has been growing at a healthy pace, is yet not a material contributor in domestic rating revenue
- Surveillance Fees (SF) were 50%+ of CY21 domestic rating revenue SF are accounted over the life of the bond/loan - Initial Rating Fees (IRF) accounted in the quarter of assignment win
- Rack rates for Initial Rating Fees (IRF) at 10 bps for Bond Rating and 4 bps for Bank Loan Rating - but yields are lower than the rack rate – notably, yields have inched-up marginally over the past few years
- The mix of new issuers and existing issuers who could be under fee cap can influence the yields on quarterly basis - if new issuers increase in the market, it would positively influence the yield in general - but in India the large 10-15 issuers dominate the market
- In case of fee arrangements with the large issuers, it is difficult to segregate BR and BLR revenues due to composite work and fees
- Pricing pressure in ratings business has not gone away co. driving better margins/profitability through market share gains and operating leverage
- Have witnessed migration of large corporates from Bond Ratings to Bank Loan Ratings market in recent years
- Capex cycle revival would be a key monitorable.

#### S&P Ratings Support (GAC)

 Added new areas of engagements like ESG assessment and analytics surveillance support – broadening of scope/support will continue driving growth

#### Global Research & Risk Solutions (GR&RS)

- Demand for CRISIL's capabilities in GR&RS business remain high underpinned by market-led changes and regulatory push
- Co. witnessing clients' spending increasing in the areas of non-financial risk, digitalization, transformation, sustainability (ESG), etc. relating to data, research, intelligence, etc. - these are additional business opportunities over traditional requirements - unlocked new opportunities by working closely with customers
- Delivered risk transformation projects for global banks strong traction for core offerings continue
- Multiple factors driving margin expansion like stronger growth, cost focus, focus on risk side, etc.



### **Global Benchmarking Analytics (GBA)**

- Leveraging the Greenwich acquisition through a) augmented capability to offer full-suite of benchmarking analytics services (quantitative and qualitative) and b) going with combined offering to existing clients (to expand share of wallet) and new clients (non-CIB customers like asset managers, community/commercial banks and other entities)
- Demand for benchmarking and competitive intelligence remains high from global financial institutions
- Greenwich had posted a loss in Q1 CY21, but was profitable for full-year 2021
- Co. targets better margins in GBA business, both for Greenwich and Coalition

#### India Research & Advisory

- India research witnessing good growth on capital market buoyancy
- Traction in Advisory Business in terms of RFPs currently way better than same time last year

   future drivers to be higher budgeted Infra capex in areas such as Roads, Ports, Logistics
   and Energy and higher allocation under PLI scheme towards renewables and sustainability
   themes

#### ESG

 Potential of ESG opportunity for CRISIL across data, research, benchmarks, evaluation, assessment, consulting, etc. – the addressable market would be decided by capabilities and focus

#### **EBITDA Margin**

- EBIDTA margins near 30% in Q1 CY22 best to look at full-year margin due to quarterly volatility/cyclicity
- Targeting growth in margins over coming years every business has headroom to deliver margin expansion going ahead – however, there would be some level of non-linearity due to strategic investment in Tech and Talent
- Hired experienced talent from the market hiring campus talent also from B schools and Top Engineering Colleges - 15% fresh talent and 85% lateral talent hired in recent quarters


Particulars (Rs mn)	Q1CY22	Q4CY21	QoQ	Q1CY21	YoY
Ratings					
Revenue	1,633	1,650	(1.0)	1,489	9.7
PBIT	778	660	17.9	703	10.6
PBIT Margin (%)	47.6	40.0		47.2	
Research					
Revenue	3,942	4,943	(20.2)	3,122	26.3
PBIT	956	1,075	(11.1)	532	79.6
PBIT Margin (%)	24.2	21.7		17.0	
Advisory					
Revenue	374	468	(20.1)	340	9.8
PBIT	41	88	(53.2)	26	58.8
PBIT Margin (%)	11.0	18.9		7.6	
Source: Company, YES Sec					

#### **Exhibit 2: Segmental Performance**



# **STORY IN CHARTS**

Exhibit 3: Revenue growth to be consistently healthy 21.0 (%) 16.1 18.0 17.3 14.4 15.0 12.9 12.1 14.1 14.3 10.1 12.0 13.6



Source: Company, YES Sec

CY14

CY15 CY16

CY13

9.0

6.0


3.0

0.0

-3.0


### Exhibit 5: Research's revenue share to witness further expansion

CY17



Source: Company, YES Sec






#### Source: Company, YES Sec

### Exhibit 6: EBITDA margin to improve with margin levers across businesses


**CY19** CY20



Source: Company, YES Sec

Source: Company, YES Sec

#### Exhibit 8: High profitability & DPR to continue



Source: Company, YES Sec




Advisory

CY22E CY23E CY24E

CY21







#### Exhibit 9: Consistent robust cash generation ensures significant liquidity on BS despite high DPR


Source: Company, YES Sec

### Exhibit 10: Core profitability metrics will improve underpinned by margin expansion and sturdy growth





Source: Company, YES Sec



#### Exhibit 11: 1 year rolling P/E band

### Exhibit 12: 1 year rolling P/E vis-à-vis the Mean



Source: Company, YES Sec



# **FINANCIALS**

### Exhibit 13: Balance sheet

Y/e 31 Mar (Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
Equity	73	73	73	73	73
Reserves	13,046	15,711	17,376	19,365	21,738
Net worth	13,118	15,784	17,449	19,438	21,811
Long-Term Provisions	214	212	233	256	282
Other financial liabilities	1,846	1,026	1,026	1,026	1,026
Total Non-Current Liabilities	2,060	1,237	1,258	1,281	1,307
Trade Payables	1,054	1,337	1,568	1,789	2,044
Other financial liabilities	2,454	2,904	3,405	3,885	4,440
Other Current Liabilities	2,380	2,908	3,410	3,891	4,447
Short-Term Provisions	839	815	897	986	1,085
Current tax liabilities (net)	162	53	58	64	70
Total Current Liabilities	6,888	8,018	9,338	10,615	12,087
Total Equity & Liabilities	22,067	25,039	28,045	31,334	35,204
Tangible Fixed Asset	410	403	403	403	403
Right of Use	2,091	1,270	1,207	1,146	1,089
Intangible Fixed Asset	1,366	1,208	1,148	1,090	1,036
Intangible Assets under development	136	55	55	55	55
Goodwill	3,759	3,727	3,540	3,363	3,195
Non-current investments	1,703	1,954	2,149	2,364	2,601
Deferred tax assets (net)	641	592	651	716	788
Long term loans and advances	246	299	329	362	398
Other non-current assets	65	33	36	40	44
Non current tax assets	797	1,157	1,273	1,400	1,540
Other financial assets	11	4	5	5	5
Total Non-Current Assets	11,223	10,702	10,796	10,945	11,154
Investments	3,057	4,495	6,068	7,736	9,864
Trade receivables	3,074	3,985	4,673	5,332	6,093
Cash and cash equivalents	2,787	2,943	3,303	3,795	4,214
ST Loans and advances	212	72	79	87	95
Other current assets	664	1,274	1,402	1,542	1,696
Other financial assets	1,049	1,568	1,725	1,898	2,087
Total Current Assets	10,844	14,337	17,249	20,389	24,050
Total Assets	22,067	25,039	28,045	31,334	35,204



### Exhibit 14: Income statement

Y/e 31 Mar (Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
Ratings	5,650	6,041	6,693	7,506	8,469
Research	12,827	15,437	18,571	21,356	24,560
Advisory	1,341	1,529	1,712	1,918	2,148
Total Revenue	19,818	23,007	26,976	30,780	35,176
Employee Expenses	10,684	12,869	14,928	16,869	19,062
Professional fees	1,084	1,239	1,214	1,385	1,583
Associate services fees	1,316	1,226	1,370	1,563	1,786
Other Expenses	1,741	1,615	1,776	1,954	2,149
EBITDA	4,993	6,058	7,688	9,009	10,597
Other Income	945	817	899	988	1,087
Depreciation	1,211	1,060	1,014	971	930
Interest Expense	144	89	72	69	65
РВТ	4,583	5,726	7,500	8,958	10,689
Tax	1,036	1,526	1,950	2,329	2,779
PAT	3,547	4,658	5,550	6,629	7,910

Source: Company, YES Sec

#### **Exhibit 15: Cashflow**

Y/e 31 Mar (Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
PBT	4,583	5,726	7,500	8,958	10,689
Depreciation	1,211	1,060	1,014	971	930
Change in working cap	2,316	(1,920)	154	92	130
Tax paid	1,036	1,526	1,950	2,329	2,779
Others	245	1,373	-	-	-
Cash flow from operations	7,320	4,712	6,718	7,692	8,970
Capex	(5,365)	38	(704)	(676)	(650)
Change in investments	(230)	(1,688)	(1,768)	(1,884)	(2,364)
Cash flow from investments	(5,595)	(1,650)	(2,472)	(2,560)	(3,014)
Free cash flow	1,725	3,062	4,245	5,132	5,956
Equity raised/(repaid)	0	0	-	-	-
Dividend (incl. tax)	2,394	3,365	3,885	4,640	5,537
Others			(3,885)	(4,640)	(5,537)
Cash flow from financing	(2,394)	(3,365)	361	492	419
Net change in cash	(669)	(303)	2,943	3,303	3,795
Op Cash	3,456	2,787	3,303	3,795	4,214
Cl Cash	2,787	2,943	7,500	8,958	10,689




## Exhibit 16: Ratio analysis

Y/e 31 Mar (Rs mn)	CY20	CY21	CY22E	CY23E	CY24E
Growth ratios (%)					
Ratings Revenue	3.7%	6.9%	10.8%	12.1%	12.8%
Research Revenue	22.8%	20.3%	20.3%	15.0%	15.0%
Advisory Revenue	-5.9%	14.0%	12.0%	12.0%	12.0%
EBITDA	9.5%	21.3%	26.9%	17.2%	17.6%
Profit Before Tax	-6.8%	24.9%	31.0%	19.4%	19.3%
Net profit	3.1%	31.3%	19.1%	19.4%	19.3%
Operating Ratios					
EBITDA Margin	25.2%	26.3%	28.5%	29.3%	30.1%
PBT Margin	23.1%	24.9%	27.8%	29.1%	30.4%
PAT Margin	17.9%	20.2%	20.6%	21.5%	22.5%
ROE	28.6%	32.2%	33.4%	35.9%	38.4%
Dividend Payout Ratio	67.5%	72.2%	70.0%	70.0%	70.0%
Per share					
EPS	48.9	63.9	76.1	90.9	108.5
Book Value	180.7	216.5	239.4	266.6	299.2
Valuation Ratios					
P/E	68.3	52.2	43.8	36.7	30.8
P/BV	18.5	15.4	13.9	12.5	11.2
Dividend Yield	1.0%	1.4%	1.6%	1.9%	2.3%



## **Recommendation Tracker**





#### DISCLAIMER

Investments in securities market are subject to market risks, read all the related documents carefully before investing.

The information and opinions in this report have been prepared by YSL and are subject to change without any notice. The report and information contained herein are strictly confidential and meant solely for the intended recipient and may not be altered in any way, transmitted to, copied or redistributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of YSL.

The information and opinions contained in the research report have been compiled or arrived at from sources believed to be reliable and have not been independently verified and no guarantee, representation of warranty, express or implied, is made as to their accuracy, completeness, authenticity or validity.D No information or opinions expressed constitute an offer, or an invitation to make an offer, to buy or sell any securities or any derivative instruments related to such securities. Investments in securities are subject to market risk. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Investors should note that each security's price or value may rise or fall and, accordingly, investors may even receive amounts which are less than originally invested. The investor is advised to take into consideration all risk factors including their own financial condition, suitability to risk return profile and the like, and take independent professional and/or tax advice before investing. Opinions expressed are our current opinions as of the date appearing on this report. Investor should understand that statements regarding future prospects may not materialize and are of general nature which may not be specifically suitable to any particular investor. Past performance may not necessarily be an indicator of future performance. Actual results may differ materially from those set forth in projections.

Technical Analysis reports focus on studying the price movement and trading turnover charts of securities or its derivatives, as opposed to focussing on a company's fundamentals and opinions, as such, may not match with reports published on a company's fundamentals.

YSL, its research analysts, directors, officers, employees and associates accept no liabilities for any loss or damage of any kind arising out of the use of this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject YSL and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

YES Securities (India) Limited (YSL) distributes research and engages in other approved or allowable activities with respect to U.S. Institutional Investors through SEC 15a-6 rules and regulations under an exclusive chaperone arrangement with Brasil Plural Securities LLC. The views and sentiments expressed in this research report and any findings thereof accurately reflect YSIL analyst's truthful views about the subject securities and or issuers discussed herein. YSIL is not registered as a broker-dealer under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC. For questions or additional information, please contact Gil Aikins (gil.aikins@brasilplural.com) or call +1 212 388 5600.

#### YES Securities (India) Limited

Registered Address: 2<sup>nd</sup> Floor, North Side, YES BANK House, Off Western Express Highway, Santacruz East, Mumbai - 400 055, Maharashtra, India.

Correspondence Address: 4<sup>th</sup> Floor, AFL House, Lok Bharti Complex, Marol Maroshi Road, Andheri East, Mumbai - 400059, Maharashtra, India.

> ① +91 22 68850521 | ⊠ research@ysil.in Website: www.yesinvest.in

#### DISCLOSURE OF INTEREST

Name of the Research Analyst

: Rajiv Mehta, Manuj Oberoi

The analyst hereby certifies that opinion expressed in this research report accurately reflect his or her personal opinion about the subject securities and no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendation and opinion expressed in this research report.

Sr. No.	Particulars	Yes/No
1	Research Analyst or his/her relative's or YSL's financial interest in the subject company(ies)	No
2	Research Analyst or his/her relative or YSL's actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report	No
3	Research Analyst or his/her relative or YSL has any other material conflict of interest at the time of publication of the Research Report	No
4	Research Analyst has served as an officer, director or employee of the subject company(ies)	No
5	YSL has received any compensation from the subject company in the past twelve months	No
6	YSL has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
7	YSL has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
8	YSL has received any compensation or other benefits from the subject company or third party in connection with the research report	No
9	YSL has managed or co-managed public offering of securities for the subject company in the past twelve months	No
10	Research Analyst or YSL has been engaged in market making activity for the subject company(ies)	No

Since YSL and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months or associates of YSL may have managed or co-managed public offering of securities in the past twelve months of the subject company(ies) whose securities are discussed herein.

Associates of YSL may have actual/beneficial ownership of 1% or more and/or other material conflict of interest in the securities discussed herein.



Registration Nos.: CIN: U74992MH2013PLC240971 | SEBI Single Registration No.: NSE, BSE, MCX & NCDEX: INZ000185632 | Member Code: BSE - 6538, NSE - 14914, MCX - 56355 & NCDEX - 1289 | MERCHANT BANKER: INM000012227 | RESEARCH ANALYST: INH000002376 | INVESTMENT ADVISER: INA000007331 | Sponsor and Investment Manager to YSL Alternates Alpha Plus Fund (Cat III AIF) SEBI Registration No.: IN/AIF3/20-21/0818 | AMFI ARN Code - 94338.

Details of Compliance Officer: Name: Vaibhav Purohit, Email id: compliance@ysil.in, Contact No: +91-22-6885 0278